Frontline Consolidation in B-ALL: Expert Insights on the Role of Blinatumomab
Update: 2025-04-08
Description
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Aaron Logan, MD, PhD
Guest: Aaron Logan, MD, PhD
Although acute lymphoblastic leukemia (ALL) is a relatively rare disease with fewer than 7,000 people diagnosed each year in the US,1,2 there’s been a lot of progress in the management of B-cell ALL over the years. One key development comes from the E1910 Phase III trial, which explored the addition of blinatumomab to frontline consolidation chemotherapy for patients with Philadelphia chromosome-negative B-lineage ALL (B-ALL).3 Joining Dr. Charles Turck to discuss the impacts of this data on B-ALL clinical guidelines and practice is Dr. Aaron Logan. Dr. Logan is a Professor of Clinical Medicine in the Division of Hematology/Oncology and Director of the Hematologic Malignancies Tissue Bank at UCSF.
References:
- National Cancer Institute. SEER Cancer Stat Facts: Acute Lymphocytic Leukemia (ALL). Accessed at https://seer.cancer.gov/statfacts/html/alyl.html on March 31, 2025
- Dana-Farber Cancer Institute. Acute Lymphoblastic Leukemia (ALL). Accessed September 17, 2024. https://www.dana-farber.org/cancer-care/types/acute-lymphoblastic-leukemia
- Litzow MR, et al. Blood. 2022;140(suppl 2):LBA-1
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
